

Removal of temporary benefits from Alberta Drug Benefit List (ADBL)

Due to the unavailability of Thiamiject 100 mg/ml Injection (DIN 02193221), manufactured by Omega Laboratories Limited, **Vitamin B1 100 mg/ml Injection USP (DIN 00816078)**, manufactured by Sandoz Canada Inc., was added as a temporary benefit for the ADBL.

Alberta Blue Cross® has confirmed that the shortage for Thiamiject 100 mg/ml Injection (DIN 02193221) has been resolved.

Vitamin B1 100 mg/ml Injection USP (DIN 00816078) will no longer be considered a temporary benefit for the ADBL **after October 2, 2025**. The above grouping was removed from the Critical Supply Product List **September 8, 2025**.

Due to the unavailability of Lodalis 625 mg Tablet (DIN 02373955), manufactured by Bausch Health, **Colesevelam 625 mg Tablet (US) (PIN 09858334)**, imported by Glenmark Pharmaceuticals Canada Inc., was added as temporary benefit for the ADBL.

Alberta Blue Cross® has confirmed that the shortage for Lodalis 625 mg Tablet (DIN 02373955) has been resolved.

As a result, **Colesevelam 625 mg Tablet (US) (PIN 09858334)** will no longer be considered a temporary benefit for the ADBL **after October 10, 2025**. This product was removed from the Critical Supply Product List **September 10, 2025**.

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at

780-498-8370 (Edmonton and area)

403-294-4041 (Calgary and area)

1-800-361-9632 (toll free)

FAX 780-498-8406 (Edmonton and area)

FAX 1-877-305-9911 (toll free)

Alberta Blue Cross offers online access to current Pharmacy Benefacts and supplemental claiming information to assist with the submission of your direct-bill drug claims.

Visit ab.bluecross.ca/providers/pharmacy-home.php

